2024-2032 年按疾病類別、藥物類別和地區分類的缺血性心臟病藥物市場報告

2023年全球缺血性心臟病（IHD）藥物IMARC Group規模達63億美元。 。

缺血性心臟病 (IHD)，也稱為冠心病，是一種透過中斷氧氣和血液供應來損害心肌的疾病。它涉及血管的分子變化或動脈粥狀硬化引起的冠狀動脈突然關閉和狹窄。這種疾病的特徵通常是慢性胸痛和嚴重不適，如果不及時治療可能致命。根據病例的嚴重程度，可以使用多種藥物來治療 IHD。例如，如果膽固醇調節藥物降低血液中的膽固醇水平，則服用阿斯匹靈來減少血液的凝血傾向，並使用BETA受體阻斷劑來降低心率和血壓。 IHD 藥物還包括鈣通道阻斷劑和雷諾嗪，可提高 BETA 阻斷劑的效率並防止冠心病進一步進展。

大眾對介入醫療手術的興趣日益濃厚，以及抗心絞痛藥物廣泛用於治療缺血性心臟病，是推動市場成長的關鍵因素之一。 IHD 藥物正被納入血管成形術、斑塊旋切術和球囊血管成形術等心臟病治療程序中，以確保健康康復並防止未來復發。此外，消費者對定期服用這些藥物的好處的認知不斷提高，也對他們的需求產生了重大影響。過度飲酒和吸煙等生活習慣以及缺乏身體活動也導致心血管疾病的盛行率不斷增加。此外，全球患有心臟病的老年人口數量不斷增加，也增加了對 IHD 藥物的需求。

本報告回答的關鍵問題：

• 迄今為止，全球缺血性心臟病（IHD）藥物市場表現如何，未來幾年將如何表現？
• COVID-19 對全球缺血性心臟病 (IHD) 藥物市場有何影響？
• 依疾病類別分類的市場是怎麼樣的？
• 根據藥物類別分類的市場是怎麼樣的？
• 全球缺血性心臟病（IHD）藥物產業的主要區域市場有哪些？
• 全球缺血性心臟病（IHD）藥物產業價值鏈的各個階段是什麼？
• 全球缺血性心臟病（IHD）藥物產業的關鍵促進因素和挑戰是什麼？
• 全球缺血性心臟病（IHD）藥物產業的結構如何？
• 全球缺血性心臟病（IHD）藥物產業的競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

• 研究目的
• 利害關係人
• 資料來源
  • 主要資源
  • 二手資料
• 市場預測
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第 3 章：執行摘要

第 4 章：簡介

• 概述
• 主要行業趨勢

第 5 章：全球缺血性心臟病 (IHD) 藥物市場

• 市場概況
• 市場業績
• COVID-19 的影響
• 市場預測

第 6 章：市場區隔：依疾病類別

• 心絞痛
  • 市場走向
  • 市場預測
• 心肌梗塞
  • 市場走向
  • 市場預測

第 7 章：市場區隔：依藥物類別

• 抗血脂異常藥物
  • 市場走向
  • 市場預測
• 鈣通道阻斷劑
  • 市場走向
  • 市場預測
• BETA-受體阻斷劑
  • 市場走向
  • 市場預測
• ACE抑制劑
  • 市場走向
  • 市場預測
• 血管張力素受體阻斷劑
  • 市場走向
  • 市場預測
• 血管擴張劑
  • 市場走向
  • 市場預測
• 抗血栓劑
  • 市場走向
  • 市場預測

第 8 章：市場區隔：按地區

• 北美洲
  • 市場走向
  • 市場預測
• 歐洲
  • 市場走向
  • 市場預測
• 亞太地區
  • 市場走向
  • 市場預測
• 中東和非洲
  • 市場走向
  • 市場預測
• 拉丁美洲
  • 市場走向
  • 市場預測

第 9 章：SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介
  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co.
  • Eisai Co., Ltd.

The global ischemic heart disease (IHD) drugs market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

Angina Pectoris

Myocardial Infarction

Breakup by Drug Class:

Anti-Dyslipidemic Drugs

Calcium Channel Blockers

Beta-Blockers

ACE Inhibitors

ARBs

Vasodilators

Antithrombotic Agents

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

• How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
• What is the breakup of the market based on the disease class?
• What is the breakup of the market based on the drug class?
• What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
• What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
• What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
• What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
• What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Class

• 6.1 Angina Pectoris
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Infarction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Anti-Dyslipidemic Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Calcium Channel Blockers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Beta-Blockers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 ACE Inhibitors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 ARBs
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Vasodilators
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Antithrombotic Agents
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Bayer AG
  • 13.3.2 Eli Lilly and Company
  • 13.3.3 Novartis International AG
  • 13.3.4 Pfizer, Inc.
  • 13.3.5 Sanofi S.A.
  • 13.3.6 Actelion Pharmaceuticals Ltd.
  • 13.3.7 Baxter International Inc.
  • 13.3.8 Boehringer Ingelheim International GmbH
  • 13.3.9 Bristol-Myers Squibb Company
  • 13.3.10 Amgen Inc.
  • 13.3.11 F. Hoffmann-La Roche AG
  • 13.3.12 GlaxoSmithKline Plc
  • 13.3.13 Merck & Co.
  • 13.3.14 Eisai Co., Ltd.

List of Figures

• Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2023
• Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2023
• Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2023
• Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
• Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
• Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2024-2032
• Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
• Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
• Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players